1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides
申请人:——
公开号:US20030216257A1
公开(公告)日:2003-11-20
The use of 1-aryl-4-haloalkyl-2-[1H]-pyridones of the formula I
1
in which the variables are as defined in claim 1, and their use as herbicides, is described.
N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them
申请人:WARNER-LAMBERT COMPANY
公开号:EP0015773A2
公开(公告)日:1980-09-17
Compounds which are N-[6-[(acylaminoacylamino or aminoacylamino) phenyl]-1,2- dihydro-2- oxonicotinyl] penicillins having the formula
and pharmaceutically acceptable salts thereof; have broad spectrum antibacterial utility. They can be produced by (a) reacting the free amino acid of the appropriate penicillin or the acid salt or silylated derivative or complex thereof with a reactive derivative of the corresponding N-6-[(acyl- aminoacylamino or aminoacylamino)-phenyl]-1,2-dihydro-2-oxonicotinic acid, or (b) reacting the free amino acid 6-aminopenicillanic acid or a related compound or the acid salt or silylated derivative thereof with a reactive derivative of the corresponding D-N-[6-[(acylaminoacylamino or amlnoacylamino)phenyl]-1,2-dihydro-oxonicotinyl]-2-substituted glycine. Pharmaceutical compositions containing the compounds, methods for treating infections using such compositions and the starting compounds are also disclosed.
TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER
申请人:Sanomune Inc.
公开号:EP2421553A1
公开(公告)日:2012-02-29
US4278681A
申请人:——
公开号:US4278681A
公开(公告)日:1981-07-14
[EN] TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER<br/>[FR] KALLICRÉINE TISSULAIRE POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE ET DU TROUBLE BIPOLAIRE
申请人:SANOMUNE INC
公开号:WO2010121358A1
公开(公告)日:2010-10-28
The invention includes methods of treating psychiatric disorders including schizophrenia, associated conditions of the schizophrenic spectrum and bipolar disorder, comprising administering tissue kallikrein (KLK1), variants or active fragments thereof. The invention also includes compositions comprising KLK1, variants, or active fragments thereof.